<DOC>
	<DOCNO>NCT01086748</DOCNO>
	<brief_summary>An inpatient/outpatient study see LY2140023 good placebo acutely ill patient schizophrenia .</brief_summary>
	<brief_title>A Study Schizophrenia Patients</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Diagnosis schizophrenia define Diagnostic Statistical Manual Mental Disorders , Fourth Edition , Text Revision ( DSMIVTR ; APA 2000 ) ( Disorganized , 295.10 ; Catatonic , 295.20 ; Paranoid 295.30 ; Undifferentiated , 295.90 ) confirm Structured Clinical Interview DSMIVTR ( SCID ) . Non pregnant female patient agree use acceptable birth control At entry study must consider moderately ill opinion investigator Willing participate minimum 3 week inpatient hospitalization must appropriate patient clinical judgment investigator . 1 year history Schizophrenia prior enter study At study entry patient history antipsychotic treatment must lifetime history least one hospitalization treatment schizophrenia , include hospitalization require study . Patients never take antipsychotic treatment may enter study even without history hospitalization . At study entry patient history antipsychotic treatment must history least one episode illness exacerbation require intensification treatment intervention care last 2 year , include present episode illness . Patients never take antipsychotic treatment may enter study without past history illness exacerbation intensification treatment last 2 year . At study entry patient must experience exacerbation illness within 2 week prior enter study , lead intensification psychiatric care opinion investigator . If exacerbation occur patient presently hospitalize , patient must hospitalize longer 60 day entry study Participated clinical trial pharmacological treatment intervention receive studyrelated medication 6 month prior visit 1 Previously complete withdrawn study , study investigate LY2140023 predecessor molecule glutamatergic activity . Treatment clozapine dose great 200 mg daily within 12 month prior enter study , receive clozapine month enter study Patients currently receive treatment ( within 1 dose interval , minimum 4 week , prior enter study ) depot formulation antipsychotic medication . Patients currently suicidal . Females pregnant , nursing , intend become pregnant within 30 day complete study . Patients uncorrected narrowangle glaucoma , uncontrolled diabetes , certain disease liver , renal insufficiency , uncontrolled thyroid condition serious unstable illness Have history one seizures , except experienced single simple febrile seizure age 6 month 5 year Patients exclude , biological father , mother , brother , sister , child history idiopathic epilepsy . Within 1 year study enrollment , patient history central nervous system infection , uncontrolled migraine , transient ischemic attack ( TIA ) , head trauma loss consciousness postconcussive Patients exclude lifetime history following : head trauma , stroke , CNS infection persistent neurological deficit ( focal diffuse ) ; brain surgery ; electroencephalogram paroxysmal ( epileptiform ) activity , brain structural lesion , include developmental abnormality , determine examination previous neuroimaging study consistent diagnosable neurological disease syndrome . Electroconvulsive therapy ( ECT ) within 3 month enter study ECT time study . Leukopenia Medical history Human Immunodeficiency Virus positive ( HIV+ ) status . Higher normal blood prolactin level Certain electrocardiogram result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>